About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Generic Pharmaceutical Association Comments on Patent Harmonization | Main | Tikvah Enters Agreement with Apkarian »

July 17, 2007

Amgen Completes Acquisition of Alantos

    By Sherri Oslick --

Alantos_pharmaceuticals In follow up to our earlier post, Amgen Inc. announced on Monday that it has completed its acquisition of Alantos Pharmaceuticals, providing Amgen with Alantos's DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes, as well as its matrix metalloproteinases platform for osteoarthritis.

Amgen

Posted at 10:04 PM in Licensing |

Comments

The comments to this entry are closed.

November 2024

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Categories

Archives

More...